SLC5A2 and type 1 diabetes mellitus: As a consequence, while dapagliflozin and sotagliflozin have been approved for the treatment of T1D in Europe, no SGLT2 inhibitors have been approved for this indication in the United States, owing to the increased risk of diabetic ketoacidosis.